Prognostic value of tumor-informed ctDNA in HPV-independent head and neck squamous cell carcinoma.

ABSTRACT:

Importance

Recurrence rates for locally advanced HPV-independent (HPV-) head and neck squamous cell carcinoma (HNSCC) are high. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assays have shown promise to improve management and surveillance in several tumor types, but their clinical utility in HPV- HNSCC remains understudied.

Objective

To evaluate the performance of a tumor-informed ctDNA-based MRD assay (PredicineBEACON) in patients with newly diagnosed, locally advanced HNSCC (LA-HNSCC).

Design

Between 12/2020 and 3/2022 ctDNA was assessed before surgery, before the start of adjuvant treatment (MRD-E), within six weeks of completion of treatment (MRD-TC), and during surveillance (MRD-S). Patients were followed for at least 12 months after treatmen

SUBMITTER: Ruiz-Torres DA 

PROVIDER: S-EPMC12870559 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature